Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03057977 · ClinicalTrials.gov registry record · Phase 3
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
A Phase 3 study of Heart Failure, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,730
- Enrollment target
- 20
- Study locations
NCT03057977 is a Phase 3 study of Heart Failure that has completed, run by Boehringer Ingelheim. The registered enrollment target is 3,730 participants, above the 2,040-participant average among 397 other Heart Failure trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT03057977, a Phase 3 study of Heart Failure, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,730 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin
Study Locations (20)
Florida
- Integrated Heart Care - Boca Raton
- Morton Plant Mease Health Care - Clearwater
- Nature Coast Clinical Research - Crystal River
- Avail Clinical Research, LLC - DeLand
- Holy Cross Hospital - Fort Lauderdale
- Integrative Research Associates - Fort Lauderdale
- Nature Coast Clinical Research - Inverness
- East Coast Institute for Research, LLC - Jacksonville
- Jacksonville Center for Clinical Research - Jacksonville
- Cardiovascular Research Center of South Florida - Miami
California
- La Mesa Cardiac Center - La Mesa
- Long Beach Center for Clinical Research - Long Beach
- VA Greater Los Angeles Healthcare System - Los Angeles
- Merced Vein and Vascular Center - Merced
- University of California Irvine - Orange
- Covigilant Research, LLC - Riverside
- University of California - Torrance
- Orange County Research Center - Tustin
- Blue Coast Cardiology - Vista
Colorado
- South Denver Cardiology Associates, PC - Littleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,730 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2020-05-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03057977
The ClinicalTrials.gov registry entry for NCT03057977 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,730 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,040-participant average among 397 other Heart Failure trials with a reported enrollment target (83% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03057977 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03057977 about?
NCT03057977 is a clinical study titled "EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)". The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
What is the current status of trial NCT03057977?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,730 participants. The study started on 2017-03-06. Estimated completion is 2020-05-28.
What conditions does trial NCT03057977 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT03057977?
The interventions under investigation include: Placebo (DRUG), Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT03057977?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03057977 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.